{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'The maximum tolerated dose (MTD) was not reached and prolonged tolerability and efficacy', 'were observed in the SVd cohort.', 'The most common treatment-related AEs in the SVd Arm were nausea, anorexia, fatigue, and', 'diarrhea, all mainly Grades 1-2, and thrombocytopenia with minimal bleeding. Peripheral', 'neuropathy (all cases unrelated to selinexor) was limited to 6 patients (Grade 1: 4 patients,', 'Grade 2: 2 patients) of which 5 had prior bortezomib exposure. This incidence rate is consistent', 'with the published data cited in the literature (discussed below) for QW bortezomib dosing.', 'Based on the results from the dose escalation phase, the recommended Phase 2 dose (RP2D) is', 'a', '5-week cycle with selinexor 100 mg QW continuous, bortezomib 1.3 mg/m\u00b2 SC QW for', 'Weeks 1 through 4, and dexamethasone 20 mg on Days 1 and 2 BIW continuous. An expansion', 'phase at the RP2D is currently ongoing with preliminary tolerability and efficacy results', 'consistent with above findings.', 'Of note, the QW recommended regimen of SVd in STOMP uses 40% less bortezomib and 25%', 'less dexamethasone compared with standard BIW (for 2 of every 3 weeks) Vd regimens, and', 'consequently is expected to have significantly less peripheral neuropathy and other significant', 'AEs than standard Vd, as well as to be more convenient for patients than standard Vd and the', 'majority of Vd combinations, which require BIW clinic visits for SC (or intravenous [IV])', 'administration of bortezomib (Richardson 2007, Dimopoulos 2016, Palumbo 2016, Bringhen', '2010).', 'These preliminary results appear to confirm the nonclinical data supporting the additive or', 'synergistic effects of selinexor in combination with PIs (Section 4.2.5), with good tolerability,', 'and support this BOSTON study of SVd versus Vd.', '4.2.7.', 'Potential Risks of Selinexor', 'At the time of the most recent Selinexor IB update, clinical experience with selinexor had been', 'evaluated in 1672 patients (as of the 31 March 2018 safety data analysis).', 'In ongoing clinical studies, the most commonly reported TEAEs have been low-grade and', 'reversible, including nausea, fatigue, anorexia, vomiting, and diarrhea; thrombocytopenia and', 'anemia, which can be higher grade, have been also reported primarily in patients with', 'hematologic malignancies.', 'In a previous study, 1 patient, heavily pretreated for recurrent pancreatic cancer, developed acute', 'cerebellar syndrome following 3 doses of selinexor at 85 mg/m\u00b2 (approximately 145 mg) BSA', 'BIW. The patient experienced abnormal speech and loss of coordination, and was unable to', 'walk. This patient recovered to near baseline with both speech and mobility over ~6 weeks. No', 'other adult patients have reported similar symptoms to date.', 'Eight tumor lysis syndrome (TLS) cases have been reported, including 5 patients with MM,', '1 patient with AML, and 2 patients with acute lymphoblastic leukemia; as of the date of this', 'amendment), including 4 patients in company-sponsored studies, 2 patients in Investigator-', 'sponsored studies, and 2 patients in the expanded access program (compassionate use). Further', 'details about these patients are provided in Section 12.1.2.3.1.', 'Confidential', 'Page 40', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '4.2.7.1.', 'Reproductive Risks for Selinexor', 'Macroscopic and microscopic changes in reproductive organs were noted during rat and monkey', 'toxicology studies, most of which partially or fully resolved during the recovery period. The', 'long-term effects of these changes on reproductive potential are unknown. Secondary', 'developmental effects due to reduced maternal body weights were also noted during a study on', 'rat embryo/fetal development.', 'It is unknown whether similar effects may occur in humans. As it is unknown whether selinexor', 'might have reproductive toxicity in humans, patients must agree to use effective contraception', '(see Contraception Requirements, Section 10.8.1) during the study and for 3 months following', 'the last dose of study treatment.', '4.3.', 'Bortezomib and Dexamethasone (Vd)', 'Bortezomib, a modified dipeptidyl boronic acid, is a reversible inhibitor of the mammalian', 'proteasome, demonstrating rapid inhibition of 20S proteasome activity in peripheral blood', 'following drug administration (Velcade Prescribing Information). Bortezomib systemic', 'exposure is equivalent following either SC or IV administration; plasma concentrations show', 'multi-exponential decline with a rapid initial phase followed by a prolonged terminal phase and', 'extensive peripheral tissue distribution. Peak PDn activity is achieved within 5 to 30 minutes', 'postdose and declines slowly over the dosing interval with 22 to 48% inhibition of 20S activity', 'observed at 48 hours postdose (Moreau 2012, Reece 2011). Bortezomib is cytotoxic to a variety', 'of cancer cell types and causes a delay in tumor growth in nonclinical tumor models, including', 'MM.', 'In the USA, Canada, and Europe, bortezomib (a first-in-class PI) is approved for the treatment of', 'both newly diagnosed and relapsed MM. In RRMM, bortezomib is given with low-dose', 'dexamethasone as a standard treatment worldwide. SC administration of bortezomib showed', 'comparable efficacy to IV administration with lower rates of all AEs, in particular high-grade', 'peripheral neuropathy (Richardson 2003, Richardson 2005, Moreau 2011). SC BIW bortezomib', 'with low-dose dexamethasone (Vd) represents a standard, approved therapy for early relapsed', 'MM despite recent approvals of new MM therapies.', 'The safety and efficacy profiles of Vd have been extensively documented in multiple', 'randomized, controlled studies. Furthermore, the well-established dose and combinability of the', 'Vd control arm have supported its use in multiple recent (NCT02136134 and NCT01568866)', 'and ongoing (NCT01734928 and NCT02755597) pivotal myeloma studies.', 'Please refer to the full prescribing information for bortezomib (different local/regional trade', 'names may be used) for the most current clinical experience and safety and reproductive risk', 'information.', '4.4.', 'Study and Dose Rationale', '4.4.1.', 'Study Rationale', 'This Phase 3 study of SVd versus Vd in patients with RRMM, who have received 1 to 3 prior', 'anti-MM regimens, is based on preliminary supportive safety and efficacy data from patients', 'with relapsed MM treated with SVd in the Phase 1b/2 Study KCP-330-017 (STOMP)', 'Confidential', 'Page 41', 'Version 4.0']\n\n###\n\n", "completion": "END"}